OTTAWA, Nov. 8, 2011 /CNW/ - Canada's Research-Based Pharmaceutical
Companies (Rx&D) President Russell Williams is pleased to announce
today the addition of Proteocyte Diagnostics Inc. as a new
biopharmaceutical member to the association representing the innovative
pharmaceutical industry in Canada.
Proteocyte Diagnostics Inc. (www.proteocyte.com) is an early stage molecular diagnostics company founded by Dr. Paul
Walfish and York Medtech Partners Inc. Proteocyte Diagnostics is
developing a diagnostic platform to provide highly accurate prognostic
assessment of cancers in individual patients.
The management team led by Dr. Ken Pritzker, President & CEO, has
extensive experience in bringing innovative cancer diagnostics to
"Rx&D is a community of industry colleagues that are focused on
innovation and that live by a well-established Code of Ethical
Practices and Transparency Guidelines," said Dr. Pritzker. "Membership
in Rx&D allows us to work more collaboratively in developing health
care solutions for Canadians."
"More and more companies are recognizing the value and benefits of
becoming a member of Rx&D. We are pleased to welcome Proteocyte into
our association as they bring their distinctive expertise which gives
us a broader foundation, making the research-based pharmaceutical
industry stronger," said Rx&D President Russell Williams.
Rx&D is the association of leading research-based pharmaceutical
companies dedicated to improving the health of Canadians through the
discovery and development of new medicines and vaccines. Our community
represents 15,000 men and women working for 50 member companies and
invests more than $1 billion in research and development each year to
fuel Canada's knowledge-based economy. Guided by our Code of Ethical
Practices, our membership is committed to working in partnership with
governments, healthcare professionals and stakeholders in a highly
SOURCE CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX
For further information: